Ibalizumab (Trogarzo) Shortage Update: What Patients Need to Know in 2026

Is Ibalizumab Currently in Shortage?

As of 2026, ibalizumab (Trogarzo) does not appear on the FDA's official drug shortage database. However, patients and providers consistently report significant access difficulties—difficulties that feel like a shortage but stem from different causes than a typical manufacturing or supply chain shortage.

Understanding the distinction matters: if the problem were a manufacturing shortage, the solution would be waiting for supply to catch up. Since the problem is structural access, there are active steps patients and providers can take today.

Why Ibalizumab Access Feels Like a Shortage

Multiple factors combine to make ibalizumab difficult to access, even though the drug is physically available:

Specialty-only distribution: Ibalizumab is dispensed exclusively through specialty pharmacies—not retail chains. It must be stored refrigerated and administered by IV.

Insurance prior authorization: Major insurers including Cigna, UnitedHealthcare, and Molina require PA before covering ibalizumab. The process requires documented evidence of MDR HIV-1 and treatment failure. Approval can take days to weeks.

Cost barrier: At approximately $9,000 or more per month, ibalizumab is unaffordable without insurance coverage or patient assistance.

Infusion center capacity: Patients need infusions every 14 days. Infusion centers in some areas have limited slots, particularly in rural or lower-resource settings.

Provider unfamiliarity: Because ibalizumab is prescribed only in narrow circumstances, many providers—including some pharmacists and primary care physicians—are unfamiliar with the access pathway, causing delays.

Who Is Most Affected by Ibalizumab Access Challenges?

Not all ibalizumab patients face the same challenges. Those most affected include:

Uninsured or underinsured patients without access to an ADAP program

Patients in rural or underserved areas far from infusion centers

Patients whose insurers have denied prior authorization and are appealing the decision

Newly diagnosed MDR HIV patients transitioning from hospitalization to outpatient care

The Stakes: Why Consistent Ibalizumab Access Is Critical

For patients who need ibalizumab, it is often one of their last effective antiretroviral options. Ibalizumab showed that over 80% of patients achieved at least a 70% viral load reduction one week after their first dose in clinical trials. Missing doses or experiencing prolonged treatment gaps can allow the virus to rebound and develop resistance even to ibalizumab itself.

If a maintenance dose is missed by 3 or more days, a new 2,000 mg loading dose must be re-administered before resuming the regular 800 mg every-2-week schedule. This is why consistent access—not just initial access—is critical.

What Patients Can Do Right Now

If you are struggling to access ibalizumab, take these steps immediately:

Call Thera Patient Support: 1-833-23-THERA (1-833-238-4372). This is the fastest path to insurance verification, PA support, and financial assistance.

Contact your HIV specialist: Urgently communicate any gaps in access. Experienced HIV physicians can expedite the PA process and may have bridge options available.

Use medfinder: medfinder.com calls infusion providers and specialty pharmacies near you to quickly identify who can fill your ibalizumab prescription.

Explore ADAP: If you are uninsured or underinsured, your state's AIDS Drug Assistance Program may cover ibalizumab.

For a step-by-step guide on locating ibalizumab, see: How to Find Ibalizumab in Stock Near You.